Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

This could be particularly important for Medicare patients (obesity drugs are ... The bottom line: We're maintaining our $580 fair value estimate for Eli Lilly, and the firm's tirzepatide molecule ...

Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture Justice Kyra Harris Bolden ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

including Medicare, do not offer reimbursement to treat obesity alone. The new approval is for people with moderate to severe obstructive sleep apnea who are also living with obesity. Eli Lilly ...

HHS estimated that, in fiscal year 2024, Medicare and Medicaid accounted for ... After dining recently with the leaders of Eli Lilly, Pfizer and PhRMA at Mar-a-Lago, Trump suggested in a separate ...

Senator Bernie Sanders (I-VT), for example, stated that “unless Medicare demands that Novo Nordisk and Eli Lilly substantially reduce the prices for these anti-obesity drugs, Medicare premiums for all ...

The Biden-Harris Administration proposes a new rule to expand coverage of anti-obesity medications for Americans with Medicare and Medicaid. Eli Lilly shares were up more than 4% at last check.